RNA specialist Wave Life Sciences has been told by Takeda that the Japanese drugmaker is to bring to an end the last facet of ...
Wave Life Sciences in a Tuesday filing with the SEC said Takeda has elected to terminate its option to continue work on ...
Takeda is walking away from the last target in a collaboration with Wave Life Scien | Takeda has brandished a termination ...
Wave Life Sciences (NASDAQ:WVE) said Takeda (NYSE:TAK) has elected not to exercise its option to further develop its ...
There is no simple solution to tackling health inequity, but we’re confident that infusing health equity principles across ...
Takeda Pharmaceutical offers a strong cash position and an above-average dividend yield. Find out why I'm bullish on TAK ...
Loh led a Willenken team that won a $505.6 million award for AbbVie Pharmaceuticals in a breach-of-contract dispute with ...
Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA ...
Pharmaceutical company Lupin has announced a non-exclusive patent licence agreement with Takeda Pharmaceutical for the ...
eVnExpress on MSN24d
Takeda marks 10 years in Vietnam with new dengue vaccine approvalTakeda, a global pharmaceutical leader, is celebrating a decade in Vietnam, emphasizing its commitment to improving ...
The T. Rowe Price Japan Fund (Trades, Portfolio), known for its strategic investments in a diverse array of Japanese industries, has recently disclosed its N-PORT filing for the third quarter of 2024.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback